Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+...
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to...
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
WOONSOCKET, R.I., June 04, 2024 (GLOBE NEWSWIRE) -- Surplus Solutions, a leader in Equipment Lifecycle Management (ELM) services, announces the...
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying...
Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an...
PetVivo Holdings, Inc. April Boyce MINNEAPOLIS, MN, US, June 04, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC Pink: PETV...
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained...
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO...
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3,...
MADISON, NJ / ACCESSWIRE / June 3, 2024 / G&L Healthcare Advisors is delighted to announce that Richard Edmunds, a...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial...
HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced...
ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its...
The state-of-the-art instrumentation will support and accelerate BioPharmaSpec’s clients’ efforts in successful biologics product developmentMALVERN, Pa. and ST. SAVIOUR, Jersey,...
Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO) Lixte Biotechnology Holdings, Inc. PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE)...
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June...